期刊文献+

吗替麦考酚酯在自身免疫性疾病患者体内的药代动力学研究 被引量:11

Pharmacokinetics of mycophenolate mofetil in adult Chinese patients with autoimmune disease
原文传递
导出
摘要 目的探讨免疫抑制剂吗替麦考酚酯(MMF)在自身免疫性疾病患者体内首次给药和稳态后的药代动力学。方法自身免疫性疾病患者14例,口服吗替麦考酚酯0.75 g,q12 h,连续服药7 d达稳态,用高效液相色谱法测定MMF的活性代谢物麦考酚酸(MPA)及二级代谢物酚化葡萄糖醛麦考酚酸(MPAG)的血药浓度,并评价2种代谢物的体内暴露药量与患者肾功能的关系。结果 MPA首次服药及稳态后的Cmax分别为(8.45±7.54),(10.89±4.37)mg·L-1,AUC0-12h分别为(41.07±49.26),(55.09±41.74)mg·h·L-1;MPAG首次及稳态后的Cmax分别为(41.24±28.57),(67.63±36.98)mg·L-1,AUC0-12h分别为(487.25±326.53),(720.79±413.86)mg·h·L-1;两者在患者个体间药代动力学参数差异均较大,且稳态后的AUC0-12h与首次给药相比均明显增大(P<0.05);MPAG的体内暴露药量与肾功能存在明显负相关(P<0.05),而MPA的体内暴露药量与患者肾功能无明显相关性(P>0.05)。结论自身免疫性疾病患者同方案给药后,MPA及MPAG血药浓度及药代动力学个体间差异大,且在体内存在明显蓄积现象。 Objective To investigate the pharmacokinetics of mycophe-nolate mofetil ( MMF) in Chinese adult patients with autoimmune disea-ses.Methods Fourteen patients with autoimmune disease were included in this study.Oral dose ( MMF 0.75 g, q12 h) was given for the first time and 7 days later steady -state.Serum concentrations of the myco-phenolic acid ( MPA) , an active metabolite of the pro -drug MMF, and its phenol glucuronide metabolite ( MPAG ) were determined by HPLC method.Pharmacokinetic parameters of MPA and MPAG were calculated and influences of renal function on MPA drug exposure and MPAG drug exposure in steady -state were investigated.Results The main pharma-cokinetic parameters of MPA after first -dose and steady -state were as follows: Cmax were ( 8.45 ±7.54 ) , ( 10.89 ±4.37 ) mg · L-1 , AUC0-12 h were (41.07 ±49.26 ), (55.09 ±41.74 ) mg· h· L-1 and the main pharmacokinetic parameters of MPAG after first -dose and steady-state were as follows: Cmax were (41.24 ±28.57 ), (67.63 ± 36.98) mg · L-1, AUC0-12h were (487.25 ±326.53 ), (720.79 ±&nbsp;413.86 ) mg· h· L-1.A large variability existed in pharmacokinetic parameters of MPA and MPAG.The differences in pharmacokinetic parameters are larger between individual patient of the two groups , the AUC0-12h of steady -state compared with the first administration were both obviously greater ( P0.05 ).Conclusion In patients with autoimmune disease receiving a fixed MMF dose , there is a large inter-individual variability of MMF pharmacokinetics and accumulation of MPA and MPAG drug exposure .In addition, a significant accumulated phenomenon was found.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2015年第2期102-105,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(81302741) 上海市卫生局科研基金资助项目(2009219) 同济大学附属杨浦医院"晨光计划"基金资助项目(Ye1201220)
关键词 吗替麦考酚酯 麦考酚酸 酚化葡萄糖醛麦考酚酸 自身免疫性疾病 药代动力学 mycophenolate mofetil mycophenolic acid mycophenolic acid glucuronide autoimmune disease pharmacokinetics
  • 相关文献

参考文献5

  • 1Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis [ J ]. N Engl J Med, 2005,353 : 2219 -2228.
  • 2郑春霞,刘志红,秦卫松,曾彩虹,黎磊石.肾小球疾病患者霉酚酸血药浓度监测及其临床意义[J].肾脏病与透析肾移植杂志,2007,16(5):406-413. 被引量:10
  • 3Zicheng Y, Peijun Z, Da X, et al. Investigation on pharmaeokinetics of mycophenolic acid in Chinese adult renal transplant patients [ J ]. Br J Clin Pharmacol, 2006,62 : 446 -452.
  • 4黄露,葛苗苗,舒成仁,黎维勇.吗替麦考酚酯软胶囊及普通胶囊在健康人体的生物等效性[J].中国临床药理学杂志,2010,26(4):275-278. 被引量:1
  • 5Neumann I, Haidinger M, Jager H, et al. Pharmacokinetics of myco- phenolate mofetil in patients with autoimmune diseases compared renal transplant recipients [ J ]. J Am Soc Nephrol, 2003,14:721 - 727.

二级参考文献38

共引文献9

同被引文献123

引证文献11

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部